Abstract
ROS1 gene rearrangements can lead to constitutively active fusion proteins that are targetable oncogenic drivers in NSCLC. Entrectinib, a potent ROS1 tyrosine kinase inhibitor (TKI), has demonstrated efficacy and CNS activity in patients with ROS1-fp NSCLC from the integrated analysis of the phase I/II studies STARTRK-1 (NCT02097810), STARTRK-2 (NCT02568267) and ALKA-372-001 (EudraCT 2012-000148-8): objective response rate (ORR) was 67% (n=108/161; data cutoff: May 1, 2019; median duration of survival follow-up: 15.8 months).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
